SHI Concludes MOU on Boron Neutron Capture Therapy System with Fujita Health University
December 25, 2024
hereinafter “SHI”) has concluded a Memorandum of Understanding (hereinafter “MOU”) to promote research and development of deep-seated tumor treatment using the Boron Neutron Capture Therapy System (hereinafter “BNCT”
This MOU is intended to contribute to the further development of cancer treatment through the sharing of expertise and knowledge possessed by the five parties
The aim of this initiative is to adapt BNCT to deeper-seated tumors by leveraging the strengths of the five parties (see table below) and solving the issue of BNCT
| Company/Organization name | Role |
|---|---|
| 인터넷 카지노vy Industries | Provide cutting edge technology based 인터넷 카지노he company’s extensive experience in development and manufacturing of BNCT equipment |
| Fujita Health University | based 인터넷 카지노he university’s track record of clinical research as a medical institution pursuing effective cancer treatments |
| Atransen Pharma | Develop and provide technologies for BNCT drugs maintaining concentration in cancer cells |
| Stella Pharma | Provide the company’s knowledge and experience of pharmaceutical research and development for the development and the manufacturing of BNCT drugs |
| Fujita | Construction of buildings using low-activation concrete suitable for BNCT equipment |
SHI will continue efforts for the future of cancer treatment through technical innovation in BNCT
[Boron Neutron Capture Therapy (BNCT)]
the cancer patient is administered a boron-containing drug for BNCT which contains boron-10
α particles (nuclei of helium atoms) and Li recoil nuclei (nuclei of lithium atoms) are emitted with an energy that causes cell damage
and this enables selective destruction at the cell level of the cancer cells that have taken up boron-10